NEW YORK, August 28, 2026, 03:10 (EDT) – Celularity stock surged 138.5% following its announcement that it expects $300 million in manufacturing revenue from MuseCell.
- Celularity finished the session at $2.10, advancing 138.5%, with 221.1 million shares traded.
- MuseCell anticipates over $300 million in purchases within five years.
- The estimate is not binding and is subject to qualification, demand and scaling.
- Celularity reported $6.2 million in cash and a net loss of $91.7 million at the close of 2025.
Celularity Inc. (NASDAQ:CELU) stock surged over 100% on Thursday, following news of a manufacturing deal that shifted the conversation over the financially challenged cell-therapy firm’s valuation.
The stock ended the session at $2.10, up 138.5%. Trading volume was 221.1 million shares, compared to a closing market capitalization of about $60.8 million Public market data.
The trigger was a manufacturing partnership in the U.S. with the private company MuseCell Innovations. Celularity will set up Dezawa MuseCells production at its Florham Park site in New Jersey.
MuseCell expects that a broader partnership may result in aggregate orders from Celularity exceeding $300 million over five years. The projection includes anticipated future programs in addition to the first project company announcement.
The headline number amounts to nearly five times Celularity’s market capitalization at close. Additionally, it surpasses more than eleven years’ worth of revenue based on the company’s projected 2025 run rate.
| Investor measure | Verified figure | Why it matters |
|---|---|---|
| Thursday close | $2.10; +138.5% | Reflects instant market response |
| Trading volume | 221.1 million shares | Indicates high activity and price swings |
| Potential purchases | >$300 million over five years | Estimate from partner; revenue not guaranteed |
| 2025 revenue | $26.6 million | Represents a 51% decline from 2024 |
| 2025 net loss | $91.7 million | Highlights capital strain |
| Year-end cash | $6.2 million | Cash buffer remains limited |
The site offers physical capacity, covering 147,215 square feet and featuring nine Grade C manufacturing suites along with six Grade D suites.
The scheduled project involves MuseCell preparation using certified perinatal, bone-marrow, and adipose sources. Related exosome and secretome products are included in the scope.
However, the financial terms are still subject to conditions. According to the release, the estimated purchase is not binding and is contingent on demand, pricing, qualification, and production volumes.
The distinction is crucial. Celularity posted 2025 revenue of $26.6 million, a decline of 51%, as its net loss increased to $91.7 million 2025 Form 10-K.
The filing disclosed $6.2 million in cash and a working-capital deficit of $68.4 million at the end of the year. Management stated there was still substantial doubt about the company’s capacity to continue as a going concern.
Risks remain elevated. There is a possibility that technology transfer could be unsuccessful, products are still awaiting FDA approval, and future funding rounds might dilute existing shareholders. Additionally, Thursday’s trading volume of 221 million shares indicates that price discovery is still highly speculative.
The following investor assessment concerns operational proof. Turning the $300 million projection into recognized revenue will require manufacturing qualification, binding orders, and incoming cash receipts.
![UK Stock Market Today 28/08/2026 [UPDATE: 08:45 BST] [3i and Miners Lift FTSE Ahead of Warsh Speech]](https://ts2.tech/wp-content/uploads/2026/08/UK-market-dashboard-2026-08-28-0842-480x384.jpg "UK Stock Market Today 28/08/2026 [UPDATE: 08:45 BST] [3i and Miners Lift FTSE Ahead of Warsh Speech]")
